Insulinoma future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
Overview
The future therapies are being worked on mTOR receptors. Drugs like Everolimus have been developed to prove their efficacy especially with those associated with MEN 1 syndrome and help maintain glycemic control in people having an insulinoma.
Future or Investigational Therapies
Future or Investigational Therapies
The future therapies are being worked on mTOR receptors. Drugs like Everolimus have been developed to prove their efficacy especially with those associated with MEN 1 syndrome.
- It is thought that insulinoma is mediated by mTOR/P70S6K signaling pathway. Thus, inhibitors of mTOR (rapamycin) or dual PI3K/mTOR (NVP-BEZ2235) have become new drugs for treating insulinoma.
- Everolimus (an oral mTOR inhibitor) have better glycemic control in people having an insulinoma.[1][2]
References
References
- ↑ Kulke MH, Bergsland EK, Yao JC (2009). “Glycemic control in patients with insulinoma treated with everolimus”. N Engl J Med. 360 (2): 195–7. doi:10.1056/NEJMc0806740. PMID 19129539.
- ↑ Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L; et al. (2012). “Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis”. J Surg Oncol. 106 (8): 972–80. doi:10.1002/jso.23176. PMID 22711648.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH